Clinical Trials Logo
  1. Home
  2. Cancer of Unknown Primary Site
  3. NCT05263700

FAPI-CUP- Evaluating FAPI as a Novel Radiopharmaceutical for Cancer of Unknown Primary — FAPI-CUP  

Cancer of Unknown Primary Site Clinical Trial

Official title:
FAPI-CUP - Evaluating FAPI as a Novel Radiopharmaceutical Targeting Cancer-associated Fibroblasts for the Diagnosis of Patients With Cancer of Unknown Primary

Clinical Trial Summary

This is a prospective single arm cohort study designed to evaluate the diagnostic ability of 68Ga-FAPI-PET/CT scan in determining likely tissue of origin in Cancer of Unknown Primary (CUP) patients not identified by standard of care. Patients with CUP will be either treatment naïve or starting second-line treatment.

Clinical Trial Description

Cancers of unknown primary (CUP) account for 3-5% of all malignancies. The prognosis of patients diagnosed with CUP is poor, with a median overall survival of 9-12 months. Despite improvements in conventional diagnostic processes, the tissue of origin (ToO) is identified in <30% of CUP patients. PET/CT is increasingly used to determine the ToO, with the most commonly used PET radiotracer being the glucose analogue fluorine-18 fluorodeoxyglucose (FDG). Although PET/CT can change CUP patient management and identify primary sites, FDG has limited sensitivity for detecting some cancers, such as CUP. It has been reported that fibroblast activation protein (FAP) is highly expressed in some tumours, including CUP. 68Ga-FAPI (experimental drug) is a radiotracer that can specifically bind to FAP, and may enable the primary cancer site to be viewed using PET imaging. It is hypothesised that the use of 68Ga-FAPI-PET/CT will increase likely ToO diagnosis from 30% with current standard of care to 60%. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05263700
Study type Interventional
Source Peter MacCallum Cancer Centre, Australia
Contact Linda Mileshkin
Phone +61 3 85595000
Email NMResearch@petermac.org
Status Recruiting
Phase N/A
Start date February 23, 2022
Completion date February 22, 2024
View Details
See also
  Status Clinical Trial Phase
Completed NCT03278600 - Tissue-of-origin Directing Therapy in Patients With Cancer of Unknown Primary Phase 3
Recruiting NCT04504604 - TCF-001 TRACK (Target Rare Cancer Knowledge) Study N/A
Completed NCT03053466 - APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors Phase 1
Active, not recruiting NCT04750109 - Carcinoma of Unknown Primary (CUP): A Comparison Across Tissue and Liquid Biomarkers
Recruiting NCT04952103 - Real World Study of Diagnosis and First-line Treatment Among Patients With Cancer of Unknown Primary in China
Recruiting NCT04969835 - A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours Phase 1
Active, not recruiting NCT03498521 - A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Phase 2
Completed NCT01845337 - Study to Compare Cardiovascular Side Effects of Teysuno Versus Capecitabine Phase 2
Active, not recruiting NCT03752333 - Trial of Pembrolizumab in Cancer of Unknown Primary Phase 2
Completed NCT05841966 - Surgeon-performed Intraoperative Transoral Ultrasound for Cancer of Unknown Primary N/A
Recruiting NCT04131621 - Nivolumab/Ipilimumab in Second Line CUP-syndrome Phase 2
Recruiting NCT04459273 - Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers Phase 1
Active, not recruiting NCT05024968 - Sintilimab in Cancer of Unknown Primary Phase 2